AstraZeneca Overview

  • Year Founded
  • 1913

Year Founded

  • Status
  • Public

  • Employees
  • 89,900

Employees

  • Stock Symbol
  • AZN

Stock Symbol

  • Investments
  • 109

  • Share Price
  • $136.12
  • (As of Friday Closing)

AstraZeneca General Information

Description

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

Contact Information

Formerly Known As
Zeneca Group, Zeneca Group Plc
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Stock Exchange
LON
Corporate Office
  • 1 Francis Crick Avenue
  • Cambridge Biomedical Campus
  • Cambridge CB2 0AA
  • England, United Kingdom
+44 020 0000 0000

AstraZeneca Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AstraZeneca Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$136.12 $135.91 $119.55 - $154.31 $213B 1.55B 2.87M $3.84

AstraZeneca Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 232,662,483 232,662,483 233,963,613 206,370,813
Revenue 45,811,000 45,811,000 44,351,000 37,417,000
EBITDA 13,121,000 13,121,000 9,004,000 5,070,000
Net Income 5,955,000 5,955,000 3,288,000 112,000
Total Assets 101,119,000 101,119,000 96,483,000 105,363,000
Total Debt 28,622,000 28,622,000 29,232,000 30,781,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AstraZeneca Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AstraZeneca‘s full profile, request access.

Request a free trial

AstraZeneca Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells brand
Pharmaceuticals
Cambridge, United Kingdom
89,900 As of 2023
000.00
000000000 00 000.00

000

rure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat null
000000000000000
Middlesex, United Kingdom
00000 As of 0000
000.00
000000000 000.00

00000

e irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat n
000000000000000
Rahway, NJ
00000 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AstraZeneca Competitors (33)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GSK Corporation Middlesex, United Kingdom 00000 000.00 000000000 000.00
Merck & Co. Corporation Rahway, NJ 00000 000.00 000000000 000.00
Novartis Corporation Basel, Switzerland 00000 0000 000000000 0000
Pfizer (Pharmaceuticals) Corporation New York, NY 00000 000.00 0000 000.00
AbbVie Corporation North Chicago, IL 00000 000.00 000000000 000.00
You’re viewing 5 of 33 competitors. Get the full list »

AstraZeneca Executive Team (94)

Name Title Board Seat Contact Info
Pascal Soriot Executive Director, Chief Executive Officer & Board Member
Aradhana Sarin Executive Director, Chief Financial Officer & Board Member
Cristian Massacesi MD Chief Medical Officer & Oncology Chief Development Officer
Jeffrey Potts JD Chief Human Resources Officer, Chief Compliance Officer & General Counsel
Robert Busch Controller
You’re viewing 5 of 94 executive team members. Get the full list »

AstraZeneca Board Members (25)

Name Representing Role Since
0000000 0000000 00 Self Board Member & Member of the Sustainability Committee 000 0000
0000 0000 AstraZeneca Board Member 000 0000
00000000 00000 AstraZeneca Executive Director, Chief Financial Officer & Board Member 000 0000
0000000 0000000 AstraZeneca Board Member & Member of the Audit Committee 000 0000
00000 00000000 AstraZeneca Board Member & Member of the Science Committee 000 0000
You’re viewing 5 of 25 board members. Get the full list »

AstraZeneca Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AstraZeneca Investments & Acquisitions (109)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
AsherBio 16-Apr-2024 00000 0000 0000 Drug Discovery
Fusion Pharmaceuticals 19-Mar-2024 0000000000 00.000 Drug Discovery 00000 000
Amolyt Pharma 14-Mar-2024 0000000000 00.000 Drug Discovery 0000 0000
Gracell 22-Feb-2024 0000000000 00000 Drug Discovery 00000 000
Icosavax 19-Feb-2024 Merger/Acquisition 00.00 Drug Discovery 00000 000
You’re viewing 5 of 109 investments and acquisitions. Get the full list »

AstraZeneca Subsidiaries (9)

Company Name Industry Location Founded
Gracell Drug Discovery Shanghai, China 2017
Icosavax Drug Discovery Seattle, WA 0000
Daiichi Sankyo Company Biotechnology Tokyo, Japan 0000
Link Medicine Biotechnology Waltham, MA 0000
AstraZeneca Pensionsstiftelse II Corporate Pension Sodertalje, Sweden 0000
You’re viewing 5 of 9 subsidiaries. Get the full list »

AstraZeneca ESG

Risk Overview

Risk Rating

Updated February, 07, 2024

22.03 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,173

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 909

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 444

Rank

0.00

Percentile

To view AstraZeneca’s complete esg history, request access »

AstraZeneca Exits (26)

Company Name Exit Date Exit Type Exit Size Status Buyers
Dizal Pharma 23-Dec-2019 00000 00000 00 Completed
  • 2 buyers
Dizal Pharma 28-May-2019 00000 00000 00 Completed
  • 2 buyers
Corvidia Therapeutics 25-Apr-2018 00000 00000 00 0000 Completed
  • 10 buyers
IVIVA 30-Mar-2018 0000 00000 00.000 Completed
  • 5 buyers
Viela Bio 13-Mar-2018 Early Stage VC 00000 Completed
  • 5 buyers
You’re viewing 5 of 26 exits. Get the full list »

AstraZeneca FAQs

  • When was AstraZeneca founded?

    AstraZeneca was founded in 1913.

  • Who is the CEO of AstraZeneca?

    Pascal Soriot is the CEO of AstraZeneca.

  • Where is AstraZeneca headquartered?

    AstraZeneca is headquartered in Cambridge, United Kingdom.

  • What is the size of AstraZeneca?

    AstraZeneca has 89,900 total employees.

  • What industry is AstraZeneca in?

    AstraZeneca’s primary industry is Pharmaceuticals.

  • Is AstraZeneca a private or public company?

    AstraZeneca is a Public company.

  • What is AstraZeneca’s stock symbol?

    The ticker symbol for AstraZeneca is AZN.

  • What is the current stock price of AstraZeneca?

    As of 19-Apr-2024 the stock price of AstraZeneca is $136.12.

  • What is the current market cap of AstraZeneca?

    The current market capitalization of AstraZeneca is $213B.

  • What is AstraZeneca’s current revenue?

    The trailing twelve month revenue for AstraZeneca is $45.8B.

  • Who are AstraZeneca’s competitors?

    GSK, Merck & Co., Novartis, Pfizer (Pharmaceuticals), and AbbVie are some of the 33 competitors of AstraZeneca.

  • What is AstraZeneca’s annual earnings per share (EPS)?

    AstraZeneca’s EPS for 12 months was $3.84.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »